This article was originally published in Start Up
Silicos NV's computational lead identification and development platform combines proprietary and commercial computational chemistry tools, and has potential in many indications such as cancer and infectious diseases, central nervous system disorders, and immunodeficiency diseases. The company is using its virtual fragment-based tools to create small molecules for both clients and for its own internal projects.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.